Source comparison
Melanotan-2 for Women Over 40: Comparison Table
Women 25–35 Baseline (100%) Low. Estrogen-protected vasculature Mild nausea, flushing (resolves in 2–4 hours) Standard protocol (0.5–1.0mg loading) Cardiovascular risk remains low if no pre-existing conditions Women 40–49 (Perimenopause) 15–25% elevated Modera
This comparison does not assign a generated winner or score.
- Women 25–35
- Baseline (100%)
- Low. Estrogen-protected vasculature
- Mild nausea, flushing (resolves in 2–4 hours)
- Standard protocol (0.5–1.0mg loading)
- Cardiovascular risk remains low if no pre-existing conditions
- Women 40–49 (Perimenopause)
- 15–25% elevated
- Moderate. Declining estrogen, emerging metabolic syndrome
- Persistent nausea, sustained hypertension (8–12 mmHg elevation)
- Reduce loading dose by 30–40% (0.3–0.6mg)
- Cardiovascular screening mandatory before use
- Women 50+ (Postmenopause)
- 25–30% elevated
- High. Loss of estrogen cardioprotection, arterial stiffness
- Severe hypertension, syncope, tachycardia (HR +15 bpm)
- Reduce loading dose by 50% or contraindicated
- Risk exceeds benefit in most cases. Alternative approaches recommended